Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients

被引:4
|
作者
Li, Shuai [1 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
breast neoplasms; core needle biopsy; surgical sample; Ki-67; change; prognosis; INTERNATIONAL EXPERT CONSENSUS; HER2; STATUS; SURGICAL SPECIMENS; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; AMERICAN SOCIETY; KI67; EXPRESSION; WOMEN; INDEX; EXCISION;
D O I
10.3389/fsurg.2022.905575
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background; To investigate the association of Ki-67 change pattern after core needle biopsy (CNB) and prognosis in HR+/HER2- early breast cancer patients. Method: Eligible patients were categorized into three groups: Low group, Elevation group, and High group. Chi-square test and logistic regression analysis were used to compare the clinic-pathological characteristics. Kaplan-Meier method was used to estimate the rates of recurrence-free interval (RFI) and breast cancer-specific survival (BCSS), which were compared via the Log-rank test. Cox proportional hazard analysis was performed to investigate independent prognostic factors. Results: A total of 2,858 patients were included: 1,179 (41.3%), 482 (16.9%), and 1,197 (41.8%) patients were classified into the low, elevation, and high groups, respectively. Age, tumor size, histological grade, lymph-vascular invasion (LVI), and ER level status were associated with Ki-67 change pattern after CNB. With a median follow-up of 53.6 months, the estimated 5-year RFI rates for the low group, elevation, and high groups were 96.4%, 95.3% and 90.9%, respectively (P < 0.001). And 5-year BCSS rates were 99.3%, 98.3% and 96.8%, respectively (P = 0.001). Compared with patients in the low group, patients in the high group had significantly worse RFI (hazard ratio [HR] 1.71, 95% confidence interval [CI] 1.16-2.54) in multivariate analysis. Conclusions: Ki-67 change after CNB was associated with prognosis in HR+/HER2- early breast cancer. Patients with Ki-67 high or elevation after CNB had an inferior disease outcome, indicating the necessity of re-evaluating Ki-67 on surgical specimens after CNB.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients
    Cecilia Pacheco-Velazquez, Silvia
    Carlos Gallardo-Perez, Juan
    Luis Aguilar-Ponce, Jose
    Villarreal, Patricia
    Ruiz-Godoy, Luz
    Perez-Sanchez, Manuel
    Marin-Hernandez, Alvaro
    Ruiz-Garcia, Erika
    Meneses-Garcia, Abelardo
    Moreno-Sanchez, Rafael
    Rodriguez-Enriquez, Sara
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2549 - 2559
  • [22] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Piudo, Natalia Chavarria
    Blancas, Isabel
    Flores, Encarna Gonzalez
    Carrasco, Fernando Henao
    Alvarez, Pilar Lopez
    Pancorbo, David Morales
    Casado, Salvador Gamez
    Garrido, Maria de la Cabeza Lomas
    Garcia, Jose Manuel Rodriguez
    Guisado, Antonia Martinez
    Vega, Adrian Sanchez
    Borrego, Manuel Ruiz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12) : 3131 - 3141
  • [23] Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
    Xiaosong Chen
    Siji Zhu
    Xiaochun Fei
    David H. Garfield
    Jiayi Wu
    Ou Huang
    Yafen Li
    Li Zhu
    Jianrong He
    Weiguo Chen
    Xiaolong Jin
    Kunwei Shen
    BMC Cancer, 15
  • [24] Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2-early breast cancer
    Gao, Weiqi
    Wu, Jiayi
    Chen, Xiaosong
    Lin, Lin
    Fei, Xiaochun
    Shen, Kunwei
    Huang, Ou
    JOURNAL OF CANCER, 2019, 10 (05): : 1110 - 1116
  • [25] Clinicopathological and molecular features of HR+/HER2- breast cancer patients with distinct endocrine resistance patterns
    Zhang, Siwei
    Wang, Han
    Zhang, Hang
    Zhuang, Qingyuan
    Zhu, Xiaohui
    Xiao, Yi
    Jiang, Yizhou
    CHINESE JOURNAL OF CANCER RESEARCH, 2025, 37 (01)
  • [26] Utilizing multimodal ultrasonography in conjunction with serum Ki-67 and HER2 tests for breast cancer detection and prognosis
    Liu, Lei
    Zong, Xiao-Jian
    Wu, Jie
    Li, Jing-Jing
    Yuan, Ping
    Cao, Jian
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2025, : 241 - 248
  • [27] Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
    Pistelli, Mirco
    Merloni, Filippo
    Crocetti, Sonia
    Scortichini, Laura
    Tassone, Laura
    Cantini, Luca
    Agostinelli, Veronica
    Bastianelli, Lucia
    Savini, Agnese
    Berardi, Rossana
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [28] The expression of KI-67 and LEF-1 in patients after breast cancer resection and its effects on patients' prognosis
    Chen, Canjian
    Lu, Xiaofeng
    JOURNAL OF BUON, 2020, 25 (02): : 627 - 633
  • [29] Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
    Peter A. Fasching
    Paul Gass
    Lothar Häberle
    Bernhard Volz
    Alexander Hein
    Carolin C. Hack
    Michael P. Lux
    Sebastian M. Jud
    Arndt Hartmann
    Matthias W. Beckmann
    Dennis J. Slamon
    Ramona Erber
    Breast Cancer Research and Treatment, 2019, 175 : 617 - 625
  • [30] Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis
    Martins-Branco, Diogo
    Nader-Marta, Guilherme
    Molinelli, Chiara
    Ameye, Lieveke
    Paesmans, Marianne
    Ignatiadis, Michail
    Aftimos, Philippe
    Salgado, Roberto
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2023, 194